Pneumocystis jirovecii Pneumonia in Human Immunodeficiency Virus Infection
Marc Siegel1, Henry Masur2, Joseph Kovacs2
1Division of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
Abstract:
The presentation of Pneumocystis pneumonia (PCP) in previously healthy men having sex with men (MSM) in San Francisco and New York City in 1981 heralded the beginning of the human immunodeficiency virus (HIV) pandemic. Despite a decreasing incidence of PCP among patients with HIV/AIDS (acquired immunodeficiency syndrome) since the advent of combination antiretroviral therapy in the mid-1990s, PCP remains one of the most common AIDS-defining opportunistic infections in the United States and Western Europe. Newer molecular diagnostic tests in conjunction with standard immunofluorescent or colorimetric tests have allowed for more rapid and accurate diagnosis. Although several effective oral and intravenous therapies exist to treat PCP, mortality rates in HIV-infected individuals remain unacceptably high, especially in those with advanced AIDS. The identification of specific mutations in Pneumocystis genes targeted by trimethoprim-sulfamethoxazole has raised concerns about the development of resistance to the drug of choice and may ultimately lead to greater utilization of alternative therapies to treat PCP in the future.
Insights
Pneumocystis pneumonia (PCP) remains a common AIDS-defining illness despite advances in HIV treatment. Concerns about drug resistance to trimethoprim-sulfamethoxazole may necessitate alternative therapies for PCP.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- Pneumocystis pneumonia (PCP) emerged with the HIV/AIDS pandemic in 1981.
- PCP is a common AIDS-defining opportunistic infection in the US and Western Europe.
- Antiretroviral therapy has decreased PCP incidence but not eliminated it.
Purpose of the Study:
- To review the current status of Pneumocystis pneumonia (PCP) in the context of HIV/AIDS.
- To highlight diagnostic advancements and therapeutic challenges.
- To address concerns regarding antimicrobial resistance in PCP treatment.
Main Methods:
- Review of diagnostic methods for PCP, including molecular and immunofluorescent assays.
- Discussion of current therapeutic options for PCP, both oral and intravenous.
- Analysis of emerging drug resistance patterns in Pneumocystis species.
Main Results:
- Newer diagnostic tests offer faster and more accurate PCP identification.
- Despite effective treatments, mortality from PCP in advanced HIV/AIDS remains high.
- Identification of mutations linked to trimethoprim-sulfamethoxazole resistance is a growing concern.
Conclusions:
- PCP continues to be a significant opportunistic infection in individuals with HIV/AIDS.
- Diagnostic accuracy has improved, but treatment outcomes require further enhancement.
- Antimicrobial resistance may drive the adoption of alternative PCP therapies in the future.
Related Concept Videos
01:29Pneumonia II: Pathophysiology
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:30Pneumonia III: Complications and Assessment
01:27Cytomegalovirus Disease
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: